Authorized Generics: How Brand Names Fight Patent Expiration
Learn how pharmaceutical companies use authorized generics to protect their revenue and market share after a drug patent expires, and how it affects patients.
Tag: Hatch-Waxman Act
Paragraph IV Certifications: How Generic Drugs Challenge Patents Early
Paragraph IV certifications let generic drugmakers challenge brand patents before launch, saving billions in drug costs. This legal tool under the Hatch-Waxman Act drives competition, delays, and settlements in the U.S. generic market.
